FindTrial
Sign In

Gemcitabine (GEM)

DRUG7 trials

Sponsors

Devalingam Mahalingam, The University of Hong Kong, First Affiliated Hospital of Wenzhou Medical University, Shenzhen Majory Biotechnology Co., Ltd., FutureGen Biopharmaceutical (Beijing) Co., Ltd

Conditions

Carcinoma in Situ of BladderCarcinoma, Transitional CellKRAS P.G12CMetastatic Pancreatic CancerNasopharyngeal CancerNasopharyngeal Cancer RecurrentNasopharyngeal Cancinoma (NPC)Nasopharyngeal Carcinoma (NPC)

Phase 1

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
WithdrawnNCT05251038
Devalingam MahalingamKRAS P.G12C, Metastatic Pancreatic Cancer, Pancreatic Cancer +1
Start: 2022-09-13End: 2023-01-31Updated: 2023-05-11
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
RecruitingNCT07235202
Shenzhen Majory Biotechnology Co., Ltd.Pancreatic Ductal Adenocarcinoma (PDAC)
Start: 2025-12-24End: 2028-12-22Target: 45Updated: 2025-12-31

Phase 2

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma
Not yet recruitingNCT07129772
The University of Hong KongNasopharyngeal Cancer Recurrent, Nasopharyngeal Cancinoma (NPC)
Start: 2025-11-01End: 2028-06-30Target: 53Updated: 2025-09-04
Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study
Not yet recruitingNCT07189793
First Affiliated Hospital of Wenzhou Medical UniversityCarcinoma in Situ of Bladder, Carcinoma, Transitional Cell, Non-Muscle-Invasive Bladder Cancer +1
Start: 2025-10-31End: 2028-10-31Target: 106Updated: 2025-09-24

Phase 3

A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer
Not yet recruitingNCT07383922
FutureGen Biopharmaceutical (Beijing) Co., LtdPancreatic Cancer
Start: 2026-02-28End: 2030-12-31Target: 524Updated: 2026-02-04
Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma
Not yet recruitingNCT07385079
Sun Yat-sen UniversityNasopharyngeal Cancer, Nasopharyngeal Cancinoma (NPC)
Start: 2026-03-01End: 2030-01-01Target: 412Updated: 2026-02-03
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
RecruitingNCT07459296
First Affiliated Hospital of Guangxi Medical UniversityNasopharyngeal Carcinoma (NPC)
Start: 2026-03-05End: 2032-04-01Target: 266Updated: 2026-03-16